Johnson & Johnson (JNJ) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 28, 2026
- EPS actual
- $2.90
- EPS estimate
- $2.85
- EPS surprise
- +1.59%
- Revenue surprise
- +1.15%
- Revenue
- $25.3B
- Revenue estimate
- $25.0B
- Reported
- Jul 15, 2026
Johnson & Johnson's Q2 2026 results, reported July 15, 2026, delivered the highest quarterly EPS in the table. Earnings per share were $2.90, beating the $2.85 estimate by 1.59%. Revenue was $25.3 billion against a $25.0 billion estimate, a 1.15% beat. Compared with Q2 2025, EPS rose 4.7% from $2.77 and revenue rose 6.8% from $23.7 billion. EPS was also up 7.4% from Q1 2026's $2.70.
The longer record is flatter. Annual EPS was $10.16 in 2022, $10.43 in 2023, $9.99 in 2024 and $10.80 in 2025. Revenue peaked in the table at $25.5 billion in Q2 2023, then dipped to $21.4 billion from Q3 2023 to Q1 2024 before recovering. Across the last 20 quarters, Johnson & Johnson beat EPS estimates 19 times. The one miss came in Q4 2025, by 2.26%. Its largest beat was 10.58%, in Q3 2021.
Johnson & Johnson has reported its third quarter between October 14 and 19 in each of the last five years, so the next report is likely in mid-October 2026. The key questions are whether EPS stays near $2.90 and whether revenue holds above $25 billion.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Jul 15, 2026 | $2.85 | $2.90 | +1.59% | $25.3B | SEC |
| Q1 2026 | Apr 14, 2026 | $2.68 | $2.70 | +0.85% | $24.1B | SEC |
| Q4 2025 | Jan 21, 2026 | $2.52 | $2.46 | −2.26% | $24.6B | SEC |
| Q3 2025 | Oct 14, 2025 | $2.76 | $2.80 | +1.54% | $24.0B | SEC |
| Q2 2025 | Jul 16, 2025 | $2.68 | $2.77 | +3.29% | $23.7B | SEC |
| Q1 2025 | Apr 15, 2025 | $2.58 | $2.77 | +7.33% | $21.9B | SEC |
| Q4 2024 | Jan 22, 2025 | $1.99 | $2.04 | +2.43% | $22.5B | SEC |
| Q3 2024 | Oct 15, 2024 | $2.21 | $2.42 | +9.68% | $22.5B | SEC |
| Q2 2024 | Jul 17, 2024 | $2.71 | $2.82 | +4.01% | $22.4B | SEC |
| Q1 2024 | Apr 16, 2024 | $2.66 | $2.71 | +2.04% | $21.4B | SEC |
| Q4 2023 | Jan 23, 2024 | $2.28 | $2.29 | +0.39% | $21.4B | SEC |
| Q3 2023 | Oct 17, 2023 | $2.52 | $2.66 | +5.71% | $21.4B | SEC |
| Q2 2023 | Jul 20, 2023 | $2.62 | $2.80 | +7.01% | $25.5B | SEC |
| Q1 2023 | Apr 18, 2023 | $2.50 | $2.68 | +7.09% | $24.7B | SEC |
| Q4 2022 | Jan 24, 2023 | $2.24 | $2.35 | +5.07% | $23.7B | SEC |
| Q3 2022 | Oct 18, 2022 | $2.48 | $2.55 | +2.93% | $23.8B | SEC |
| Q2 2022 | Jul 19, 2022 | $2.54 | $2.59 | +2.09% | $24.0B | SEC |
| Q1 2022 | Apr 19, 2022 | $2.59 | $2.67 | +3.28% | $23.4B | SEC |
| Q4 2021 | Jan 25, 2022 | $2.12 | $2.13 | +0.64% | $24.8B | SEC |
| Q3 2021 | Oct 19, 2021 | $2.35 | $2.60 | +10.58% | $23.3B | SEC |
Quarterly revenue
Frequently asked questions
When did Johnson & Johnson (JNJ) last report earnings?
Johnson & Johnson last reported on Jul 15, 2026, covering fiscal Q2 2026.
Did JNJ beat earnings estimates?
Yes. Johnson & Johnson reported EPS of $2.90 for Q2 2026 against a $2.85 estimate — a 1.59% beat.
How much revenue did JNJ report last quarter?
Johnson & Johnson reported $25.3B in revenue for Q2 2026, against a consensus estimate of $25.0B.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.